NO20065780L - Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor - Google Patents

Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor

Info

Publication number
NO20065780L
NO20065780L NO20065780A NO20065780A NO20065780L NO 20065780 L NO20065780 L NO 20065780L NO 20065780 A NO20065780 A NO 20065780A NO 20065780 A NO20065780 A NO 20065780A NO 20065780 L NO20065780 L NO 20065780L
Authority
NO
Norway
Prior art keywords
inhibitor
src kinase
egfr
kinase inhibitor
azdo
Prior art date
Application number
NO20065780A
Other languages
English (en)
Inventor
Tim Paul Green
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20065780L publication Critical patent/NO20065780L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår en kombinasjon for anvendelse i synergistisk behandling av brystkreft omfattende et antiøstrogen og Src kinase-inhibitoren AZD0530, en kombinasjon for synergistisk behandling av kreft omfattende en EGFR TKI og Src kinase-inhibitoren AZD0530 og en trippelkombinasjon for synergistisk behandling av brystkreft omfattende et antiøstrogen, en EGFR TKI og Src kinase-inhibitoren AZD0530.
NO20065780A 2004-05-29 2006-12-13 Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor NO20065780L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0412074.7A GB0412074D0 (en) 2004-05-29 2004-05-29 Combination product
PCT/GB2005/002102 WO2005117888A1 (en) 2004-05-29 2005-05-26 Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor

Publications (1)

Publication Number Publication Date
NO20065780L true NO20065780L (no) 2006-12-21

Family

ID=32671309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065780A NO20065780L (no) 2004-05-29 2006-12-13 Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor

Country Status (17)

Country Link
US (2) US20070254893A1 (no)
EP (1) EP1763352B1 (no)
JP (1) JP2008501006A (no)
KR (1) KR20070034510A (no)
CN (2) CN1960733B (no)
AU (1) AU2005249264B2 (no)
BR (1) BRPI0511475A (no)
CA (1) CA2566380C (no)
ES (1) ES2392972T3 (no)
GB (1) GB0412074D0 (no)
HK (1) HK1103625A1 (no)
IL (1) IL178939A (no)
MX (1) MXPA06013861A (no)
NO (1) NO20065780L (no)
NZ (1) NZ550977A (no)
WO (1) WO2005117888A1 (no)
ZA (1) ZA200609597B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0625691D0 (en) * 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
EP2134854B1 (en) * 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
US20100069340A1 (en) * 2008-09-11 2010-03-18 Wyeth Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2016130897A1 (en) * 2015-02-13 2016-08-18 Yu Paul B Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
CN114288410B (zh) * 2022-01-28 2023-05-05 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Src抑制剂和fak抑制剂在制备用于抑制肺癌转移的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
GB0625691D0 (en) 2006-12-22 2007-01-31 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
US20070254893A1 (en) 2007-11-01
IL178939A0 (en) 2007-03-08
MXPA06013861A (es) 2007-01-26
WO2005117888A1 (en) 2005-12-15
ZA200609597B (en) 2008-08-27
CN101664554A (zh) 2010-03-10
KR20070034510A (ko) 2007-03-28
CA2566380C (en) 2012-04-17
EP1763352A1 (en) 2007-03-21
AU2005249264B2 (en) 2009-01-15
US20110028488A1 (en) 2011-02-03
US8680109B2 (en) 2014-03-25
ES2392972T3 (es) 2012-12-17
JP2008501006A (ja) 2008-01-17
CA2566380A1 (en) 2005-12-15
BRPI0511475A (pt) 2007-12-26
IL178939A (en) 2015-11-30
EP1763352B1 (en) 2012-09-12
AU2005249264A1 (en) 2005-12-15
NZ550977A (en) 2009-02-28
GB0412074D0 (en) 2004-06-30
CN1960733B (zh) 2010-12-08
CN1960733A (zh) 2007-05-09
HK1103625A1 (en) 2007-12-28

Similar Documents

Publication Publication Date Title
NO20065780L (no) Kombinasjonsprodukt omfattende SRC kinase inhibator AZDO 530 og en antiostrogen eller EGFR-TK- inhibitor
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20082292L (no) Antiproliferativ kombinasjonsterapi ved anvendelse av visse platinumbaserte kjemoterapeutiske virekemiddel og EGFR inhibitorer eller pyrimidine analoger
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TW200801008A (en) Protein kinase inhibitors
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
ECSP066750A (es) Derivados de indazol como inhibidores de lipasas sensibles a hormonas
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2007115289A8 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application